Pancreaticobiliary cancer: The future aspects of medical oncology

J. M G H Van Riel, G. Giaccone, H. M. Pinedo

Research output: Contribution to journalArticlepeer-review

Abstract

Pancreatic cancer is one of the most common and most lethal cancers in the Western world with a median survival of approximately 3 months. Thus far, the results of anti-cancer treatment have been dismal, with a median survival of only 20 months in resectable pancreatic cancer, and 6 months in advanced disease. Although combined chemoradiation results in improved local control, it has only a modest impact on survival due to the development of distal metastases. In this review we will discuss the progress made in the treatment of pancreatic cancer over the past few years and discuss future therapies such as: immunoradiotherapy, matrix metalloproteinase inhibitors, antiangiogenesis therapies, gene therapy, immunotherapy, ONYX015, and farnesylation inhibitors.

Original languageEnglish (US)
JournalAnnals of Oncology
Volume10
Issue numberSUPPL. 4
StatePublished - 1999
Externally publishedYes

Keywords

  • Antiangiogenesis therapies
  • Chemoradiation
  • Farnesylation inhibitors
  • Gemcitabine
  • Gene therapy
  • Immunoradiotherapy
  • Immunotherapy
  • Matrix metalloproteinase inhibitors
  • ONYX015
  • Pancreatic cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Pancreaticobiliary cancer: The future aspects of medical oncology'. Together they form a unique fingerprint.

Cite this